Navigation Links
Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes
Date:8/30/2009

I SEPIA-ACS1/ TIMI-42 study randomized 3241 patients from 36 countries in 6 treatment arms. The study assessed the efficacy and safety of five different doses of otamixaban versus the standard unfractionated heparin plus Glycoprotein IIb/IIIa inhibitor (eptifibatide), on background of standard dual antiplatelet therapy, in patients with high-risk non-ST-elevation acute coronary syndromes. SEPIA-ACS1 study showed that otamixaban displayed clinically meaningful activity on the primary endpoint from the threshold dose of 0.070 mg/kg/h, the second tested dose, with a consistent antithrombotic effect up to the 5th highest tested dosage. The lowest studied dosage was prematurely stopped due to insufficient activity, based on recommendation by an independent data monitoring board. Moreover a combined analysis of the intermediate doses (0.105 and 0.140 mg/kg/h) of otamixaban arms showed that otamixaban reduced by approximately 46 percent (p=0.0198) the risk of the composite of death or a second myocardial infarction, a predefined study secondary efficacy endpoint.

The potent antithrombotic effect of otamixaban was also accompanied with a dose-dependent bleeding profile. Combined intermediate otamixaban dosages showed a safety profile not statistically different with regard to TIMI major or minor bleeding through 7 days, in comparison to UFH and GPIIb/IIIa inhibitor comparator (RR 1.20, 95% CI 0.64-2.27, p=0.5634).

"The SEPIA-ACS1 trial is providing very encouraging results for a new and more effective treatment approach," said Marc Cluzel, MD Senior Vice President Research and Development Sanofi-aventis. "We aim, on the basis of these findings to address through our development program remaining patients', practionners' and payers' needs for management of ACS."

Acute Coronary Syndromes is a general term used to regroup clinical symptoms related to acute myocardial ischemia. ACS represents an area of important
'/>"/>

SOURCE Sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of PLAVIX(R) in Acute Coronary Syndrome Patients Undergoing Angioplasty
2. Gen-Probe Begins U.S. Clinical Study of PROGENSA(R) PCA3 Assay, New Molecular Test to Help Assess Prostate Cancer Risk
3. Lurasidone Demonstrated Efficacy in Treating Patients With Schizophrenia in Pivotal Phase 3 Study
4. Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study
5. CardioDx Completes Validation Study of First-Of-Its-Kind Genomic Test for Coronary Artery Disease
6. R-Tech Ueno Completes Subject Enrollment in Phase 2 Clinical Study of 0.15% UF-021
7. WorldHeart Receives US Clinical Study Approval for the Levacor(TM) VAD
8. Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinsons Disease
9. Study Links Fetal Fibronectin Testing with Changes in Management Decisions for Symptomatic and Asymptomatic Women at Risk for Preterm Birth
10. Study of Lacrisert(R) Dry Eye Insert Published in The Ocular Surface
11. Amarex Clinical Research Selects OmniComm Systems to Provide eClinical Solutions for Phase III Medical Device Study and Joins OmniComms CRO Preferred Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... DIEGO , May 26, 2015 ... a clinical-stage biopharmaceutical company leveraging its molecular adhesion ... therapies for sickle cell disease, heart failure, and ... an open-label, multicenter Phase 3 extension study of ... as "EPIC-E."  The study will enroll patients who ...
(Date:5/26/2015)... , May 26, 2015  Accuray Incorporated (Nasdaq: ... is scheduled to present at the Jefferies 2015 Healthcare ... Wednesday, June 3, 2015 at 2:30pm ET.   ... available on the Investor Relations page of the Company,s ... the presentation will begin approximately one hour after the ...
(Date:5/26/2015)... 26, 2015 Egalet Corporation (Nasdaq: ... company focused on developing, manufacturing and marketing innovative ... , president and chief executive officer, is scheduled ... will provide an update on Egalet,s marketed product ... Spray, approved product OXAYDO ™ (oxycodone HCI, ...
Breaking Medicine Technology:Mast Therapeutics Announces Initiation Of EPIC-E Study 2Mast Therapeutics Announces Initiation Of EPIC-E Study 3Mast Therapeutics Announces Initiation Of EPIC-E Study 4Mast Therapeutics Announces Initiation Of EPIC-E Study 5Egalet to Present at Upcoming Conferences in June 2Egalet to Present at Upcoming Conferences in June 3
... 2, 2011 Aoxing Pharmaceutical (NYSE Amex: ... company focusing on research, development, manufacturing and distribution ... operating subsidiary in China, Hebei Aoxing Pharmaceutical Group ... State Intellectual Property Office of The People,s Republic ...
... TARRYTOWN, N.Y., May 2, 2011 Regeneron Pharmaceuticals, Inc. (Nasdaq: ... of America Merrill Lynch 2011 Health Care Conference on Tuesday, ... Eastern Time).  The session may be accessed through the Company,s ...  An archived version of the presentation will be available after ...
Cached Medicine Technology:Aoxing Pharmaceutical Company Announces Issuance of Chinese Patent for Naloxone Sublingual Film 2Aoxing Pharmaceutical Company Announces Issuance of Chinese Patent for Naloxone Sublingual Film 3
(Date:5/26/2015)... 3,000 senior industry executives are expected at ... future of the connected car. A very special attraction ... can read a driver’s brain waves. Visitors to its ... by mind alone just by gripping the steering wheel! ... are working on cognitive load, altering music based on ...
(Date:5/26/2015)... CO (PRWEB) May 26, 2015 It ... diverse community foundation in Colorado. On Wednesday, May 13, ... ushered in a new era of community-based giving with ... Titled “Our Future in the Making,” the event celebrated ... The Denver Foundation to mobilize resources for good. , ...
(Date:5/26/2015)... On May 26, 2015, My Positive Perspective ... distributor Dwayne Windfall. At the start of the episode, Deierlein ... some unique characteristics with it, so could you tell people ... saying, “I was reading the newspaper looking for a job ... looking for a person with hustle. I responded to the ...
(Date:5/26/2015)... Allprovide, the all-natural raw pet food company, today ... now available in three Georgia stores: Pooch-n-Paws in Suwannee; ... Dog Company in Kennesaw. , Allprovide is based out ... climate controlled facility. The fresh ingredients come from select ... food is triple-tested for quality. Unlike most pet foods, ...
(Date:5/26/2015)... CIO Review has chosen SIGNiX for its ... Technology Solution Providers. The positioning is based on an evaluation ... applicable across the entire security spectrum of transactions within life ... , “SIGNiX has been on our radar for some time ... Technology space, and we are happy to showcase them this ...
Breaking Medicine News(10 mins):Health News:The World’s Biggest Connected Car Exhibition is Back in Detroit 2Health News:The World’s Biggest Connected Car Exhibition is Back in Detroit 3Health News:Celebrating "Our Future in the Making" 2Health News:Celebrating "Our Future in the Making" 3Health News:My Positive Perspective Broadcasts Episode with Oceans 6 to Discuss Their Role in Helping the Community 2Health News:Allprovide, the All-Natural Pet Food, Available At Georgia Retailers 2Health News:CIO Review Selects SIGNiX as a 20 Most Promising Pharma and Life Sciences Technology Solution Provider in 2015 2Health News:CIO Review Selects SIGNiX as a 20 Most Promising Pharma and Life Sciences Technology Solution Provider in 2015 3
... PALO ALTO, Calif., April 23 Jazz,Pharmaceuticals, Inc. ... Cozadd, the,company,s Executive Chairman, will provide a corporate ... in Key Biscayne, FL,on May 1, 2008 at ... of the presentation may be accessed by visiting ...
... Technology could one day guide individualized therapy for cancer ... research suggests that scientists are close to developing a ... doctors a heads-up about what kind of treatment is ... into an emerging trend of individualized treatment for patients ...
... Inc. is pleased,to announce Corso Rehabilitation and Physical ... York State to offer the innovative and,non-surgical SpineSix ... pain,patients. Owned and operated by Gary Corso, MS, ... and Physical Therapy Associates provides,outstanding individualized care and ...
... Cream and, Limited-edition CD at Participating Giant Stores on Saturday, May ... ... April 23 ,Everyone,s a winner when you stop into participating Giant stores,throughout ... Triple Winner Game(R) Scoop Day event., This year, EDY,S Grand Ice ...
... 18% to $1.09; ... year, FRANKLIN LAKES, N.J., April 23 BD ... record quarterly revenues,of $1.747 billion for the second fiscal ... percent over the prior year period. This,quarter,s revenue growth ...
... Hurdles To Government Oversight & Gaining ... ... improved,governance structure, the benefits of nanotechnology may be difficult to,fully realize ... director of the Project on Emerging,Nanotechnologies (PEN). Rejeski testifies on Thursday, ...
Cached Medicine News:Health News:Scan Detects Oxygen Levels in Tumors 2Health News:The Future of Spine Care Has Just Gotten Better With the Use of SpineSix BioMotion Spinal System(TM) 2Health News:EDY'S(R) SLOW CHURNED(R) and Giant Food Markets Announce Scoop Day With Sweet Deals to Support the Fight Against Childhood Cancer 2Health News:BD Announces Results for Second Fiscal Quarter 2Health News:BD Announces Results for Second Fiscal Quarter 3Health News:BD Announces Results for Second Fiscal Quarter 4Health News:BD Announces Results for Second Fiscal Quarter 5Health News:BD Announces Results for Second Fiscal Quarter 6Health News:BD Announces Results for Second Fiscal Quarter 7Health News:BD Announces Results for Second Fiscal Quarter 8Health News:BD Announces Results for Second Fiscal Quarter 9Health News:BD Announces Results for Second Fiscal Quarter 10Health News:BD Announces Results for Second Fiscal Quarter 11Health News:BD Announces Results for Second Fiscal Quarter 12Health News:BD Announces Results for Second Fiscal Quarter 13Health News:BD Announces Results for Second Fiscal Quarter 14Health News:BD Announces Results for Second Fiscal Quarter 15Health News:Improved Governance Needed To Realize Nanotech's Benefits 2
... The VitalView™ Central Station is ... Criticare bedside monitors for vital signs ... displayed in real time, with simultaneous ... ECG events, graphical and tabular trends ...
... These specialty Eraser instruments have ... surgeon with the right tool for ... introduced a series of 25 gauge ... provide discrete treatment of target tissues ...
... Chart Manager provides powerful workflow tools such ... integrated transcription services, and customized flow sheets ... eliminates the need for paper charts. ... a paperless office now and can easily ...
... The Cerner PowerChart Electronic Medical ... solutions designed to create an enterprise-wide, ... (EMR). PowerChart streamlines the workflow process ... access to the functions that support ...
Medicine Products: